Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Verve Therapeutics

Main focus: Gene editing for the treatment of genetic cardiovascular diseases

Company stage: Pre-clinical

Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia

Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a

Funding stage: Public (NASDAQ:VERV)

Location: Cambridge, MA, USA



Partners: Beam Therapeutics

Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.


HashtagVerve Therapeutics, Inc.

Company: Verve Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine